Answers are grounded in this paper and cite their sources.
Rare genetic variants are increasingly recognized as contributors to neuropsychiatric disease and may reveal underlying pathobiological mechanisms. The dopamine transporter (DAT), encoded by SLC6A3, regulates dopaminergic neurotransmission through rapid dopamine (DA) reuptake. Although disease-associated DAT variants have been linked to disorders ranging from infantile parkinsonism to neuropsychiatric disease, the molecular basis of DAT dysfunction remains poorly understood. Here, we systematically investigated 55 DAT missense variants identified in the iPSYCH2012-nested case-control cohort. By assessing transport activity, inhibitor binding, cell-surface expression, subcellular localization, amphetamine responsiveness and constitutive DA efflux, we resolved the variants into seven phenotypic classes. These reflected distinct molecular defects, including impaired substrate and ion coupling, destabilized intramolecular interactions, and defective folding, trafficking or surface expression. Molecular dynamics simulations provided structural insight into representative variants. Collectively, our findings reveal mechanistic convergence of genetically diverse DAT variants and establish a framework for interpreting the pathogenicity of newly identified SLC6A3 variants.
No takes yet. Share an insight, caveat, or question.
Campana et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: